# EV-302 (NCT04223856)

> Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04223856
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Astellas Pharma Global Development, Inc.
- Conditions: Urothelial Cancer
- Interventions: Enfortumab vedotin; Pembrolizumab; Cisplatin; Carboplatin; Gemcitabine
- Enrollment: 886
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 454
- YouTube: 203
- Podcasts: 186
- X videos: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=ev-302-nct04223856

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04223856", "email": "<work email>"}; the inbox owner confirms by the emailed link.